AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04918810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel intermittent
Description: After 3 or 4 cycles of docetaxel chemotherapy (75mg/m\^2 every 21 days or 50mg/m\^2 every 14 days) in combination with an undetectable mGSTP1 level, patients will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days or 28 days (depending on Docetaxel regimen) and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
Study NCT03961945 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sponge Capsule
Description: Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
Study NCT06406231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparing efficacy of TENS and PEMF in knee osteoarthritis
Description: Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups.
Study NCT05216328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol Only Product in Oral Dose Form
Description: Information already included in arm/group description.
Study NCT05216328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium hydroxide 724mg
Description: Information already included in arm/group description.
Study NCT05686317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards APTURE transcatheter shunt system
Description: Treatment with APTURE shunt
Study NCT05686317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: CS angiography
Study NCT05705531 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection
Study NCT05705531 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Undergo medical record abstraction
Study NCT05705531 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05705531 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT05947799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline questionnaires
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.
Study NCT05947799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post-questionnaire
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
Study NCT05111626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Bemarituzumab will be administered as intravenous (IV) infusion.
Study NCT05111626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as IV infusion.
Study NCT05111626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered as IV infusion.
Study NCT05111626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.
Study NCT05111626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.
Study NCT05111626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IV infusion.
Study NCT05635773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Alexa Visual Cognitive aid
Description: The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
Study NCT05635773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Alexa Visual Cognitive aid
Description: The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
Study NCT06502314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management training
Description: It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~.
Study NCT05091879 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Multigene pharmacogenomics test
Description: This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
Study NCT05613920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet management program based on the nudge strategy
Description: The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
Study NCT00864409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0,2%
Description: Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
Study NCT00864409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline.9%
Description: Wound infiltration with 170 mL sterile saline
Study NCT06045429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oroxid®
Description: All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash.
Study NCT06045429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine
Study NCT04556682 — intervention group
Intervention type: DEVICE
Intervention: Rotational atherectomy
Description: Device used for severely calcified coronary lesion preparation before stent implantation.
Study NCT04556682 — intervention group
Intervention type: DEVICE
Intervention: Intravascular lithotripsy
Description: Device used for severely calcified coronary lesion preparation before stent implantation.
Study NCT05063344 — intervention group
Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx Syphilis Test
Description: For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.
Study NCT06169020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting and maximal oxygen consumtion
Description: All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
Study NCT06169020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free living energy expenditure
Description: All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
Study NCT06390124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Derived Growth Factor (PDGF)
Description: Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
Study NCT05711069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stability Exercise Program
Description: Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
Study NCT05711069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Football Training Program
Description: Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
Study NCT04696068 — intervention group
Intervention type: OTHER
Intervention: Porcelain plates
Description: The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
Study NCT06136533 — intervention group
Intervention type: OTHER
Intervention: Assessment-OHS
Description: Demographic information of individuals diagnosed with OHS without sarcopenia risk is recorded.Bioelectrical Impedance Analysis is used to analyze body composition.The comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index',sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index' and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'.The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'.Patients' physical activity levels are monitored with a pedometer.Quadriceps muscle strength is measured with Hand-held dynamometer and grip strength is measured with Jamar hand dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with 'Nottingham Health Profile' and 'Functional Outcomes of Sleep Questionnaire'.
Study NCT06136533 — intervention group
Intervention type: OTHER
Intervention: Assessment-Sarcopenic Obesity With OHS
Description: The sarcopenia diagnostic algorithm is used as a reference in the assessment of the presence of sarcopenic obesity. Demographic information of patients diagnosed with sarcopenic obesity is recorded. Then, the comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index', sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index', and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'. The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'. Patients' physical activity levels are monitored with a pedometer. Quadriceps muscle strength is measured with Hand-held dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with the 'Nottingham Health Profile' and the 'Functional Outcomes of Sleep Questionnaire'.
Study NCT06407323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Personalized vibration therapy powered by AI
Description: A target frequency of either 20 Hz or 25 Hz, and amplitude 2-4 mm The whole treatment session will be around 20 minutes along with hot pack as a baseline treatment, consisted of 6 sessions per week for total 8 weeks of duration
Study NCT06407323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy treatment
Description: A selected physical therapy treatment program for spastic diplegic CP.
Study NCT05569681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin 3500
Description: Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals
Study NCT05569681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin 5000 IU
Description: Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals
Study NCT06258538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robots can aid in distal UE rehabilitation through exoskeleton (EXO)
Description: Exoskeleton robot-assisted therapy Each EXO robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Hand of Hope (HOH) robotic hand system . HOH is an exoskeleton type of robot that is worn on the dorsal side of the impaired hand with 2 surface EMG sensors attached to the extensor digitorum and flexor digitorum superficialis.
Study NCT06258538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End-effector robot-assisted therapy (EE)
Description: Each EE robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Amadeo robotic system. Amadeo is an end-effector robot with 5 finger slides, which are attached to the fingertips and the thumb via magnetic finger pads. The integrated sensor for each finger allows the robot system to provide patients with real-time visual feedback of finger strengths and range of motion
Study NCT06258538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral task-oriented therapy
Description: The therapy will focus on task-oriented therapy with the affected UE and the training tasks involve proximal or distal UE movement, such as ringing a bell, picking up coins, grasping and releasing various cups, and other functional movements involved in daily activities. The level of challenge will be adapted according to patient ability and improvement during training.
Study NCT06258538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral task-oriented therapy
Description: The therapy will focus on task-oriented therapy with the affected UE and the training tasks involve proximal or distal UE movement, such as ringing a bell, picking up coins, grasping and releasing various cups, and other functional movements involved in daily activities. The level of challenge will be adapted according to patient ability and improvement during training.
Study NCT06514118 — intervention group
Intervention type: RADIATION
Intervention: residual tumor irradiation
Description: lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total
Study NCT06258538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilateral task-oriented therapy
Description: The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.
Study NCT06258538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral task-oriented therapy
Description: The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.
Study NCT05565248 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VCTX211
Description: CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device
Study NCT05818228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
Study NCT06465862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruTag System
Description: TruTag technology system, consisting of microparticle-tagged Biktarvy and companion smartphone app.
Study NCT06465862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy Pill
Description: Biktarvy prescribed with TruTag system and tagged with TruTag microparticles.
Study NCT05653479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPB-101
Description: UPB-101 Subcutaneous injection
Study NCT06400186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity gait training in varying external environments
Description: Participants will engage in two 45-minutes treadmill-based gait training sessions. These training sessions will occur on separate days. One session will be performed in a natural unmodified environment. One session will be performed in a movement amplification environment. The goal of each session will be to achieve 40-minutes of walking within a target heart rate range of 70-85% of estimated heart rate max. Each session will begin and end with a 2.5 minute warm-up and cool down respectively. Participants will be given rest breaks as needed.
Study NCT06400186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill walking in varying external environments
Description: Participants will perform a series of treadmill walking trials. Each trial will consist of 400 total steps. The first 100 steps will be performed in a natural unmodified environment. The next 200 steps will be performed in 1 of 3 external environments (natural unmodified, movement amplification, or unpredictable lateral perturbations). The final 100 steps will be performed in a natural unmodified environment. Participants will be given rest breaks between trials.
Study NCT05395117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin
Study NCT05900024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Funk It Cycle Bites
Description: The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2930 for injection
Description: TQB2930 for injection is a HER2 bispecific antibody.
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: It is an anti-microtubule chemotherapy drug
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsule
Description: TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.